Unknown

Dataset Information

0

Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies.


ABSTRACT: Cancer therapy is a strategic measure in inhibiting breast cancer stem cell (BCSC) pathways. Naringenin, a citrus flavonoid, was found to increase breast cancer cells' sensitivity to chemotherapeutic agents. Bioinformatics study and 3D tumorsphere in vitro modeling in breast cancer (mammosphere) were used in this study, which aims to explore the potential therapeutic targets of naringenin (PTTNs) in inhibiting BCSCs. Bioinformatic analyses identified direct target proteins (DTPs), indirect target proteins (ITPs), naringenin-mediated proteins (NMPs), BCSC regulatory genes, and PTTNs. The PTTNs were further analyzed for gene ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, protein-protein interaction (PPI) networks, and hub protein selection. Mammospheres were cultured in serum-free media. The effects of naringenin were measured by MTT-based cytotoxicity, mammosphere forming potential (MFP), colony formation, scratch wound-healing assay, and flow cytometry-based cell cycle analyses and apoptosis assays. Gene expression analysis was performed using real-time quantitative polymerase chain reaction (q-RT PCR). Bioinformatics analysis revealed p53 and estrogen receptor alpha (ER?) as PTTNs, and KEGG pathway enrichment analysis revealed that TGF-ß and Wnt/ß-catenin pathways are regulated by PTTNs. Naringenin demonstrated cytotoxicity and inhibited mammosphere and colony formation, migration, and epithelial to mesenchymal transition in the mammosphere. The mRNA of tumor suppressors P53 and ER? were downregulated in the mammosphere, but were significantly upregulated upon naringenin treatment. By modulating the P53 and ER? mRNA, naringenin has the potential of inhibiting BCSCs. Further studies on the molecular mechanism and formulation of naringenin in BCSCs would be beneficial for its development as a BCSC-targeting drug.

SUBMITTER: Hermawan A 

PROVIDER: S-EPMC7873751 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and <i>in vitro</i> studies.

Hermawan Adam A   Ikawati Muthi M   Jenie Riris Istighfari RI   Khumaira Annisa A   Putri Herwandhani H   Nurhayati Ika Putri IP   Angraini Sonia Meta SM   Muflikhasari Haruma Anggraini HA  

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 20201215 1


Cancer therapy is a strategic measure in inhibiting breast cancer stem cell (BCSC) pathways. Naringenin, a citrus flavonoid, was found to increase breast cancer cells' sensitivity to chemotherapeutic agents. Bioinformatics study and 3D tumorsphere <i>in vitro</i> modeling in breast cancer (mammosphere) were used in this study, which aims to explore the potential therapeutic targets of naringenin (PTTNs) in inhibiting BCSCs. Bioinformatic analyses identified direct target proteins (DTPs), indirec  ...[more]

Similar Datasets

| S-EPMC10006750 | biostudies-literature
| S-EPMC8161407 | biostudies-literature
| S-EPMC8046396 | biostudies-literature
| S-EPMC6469163 | biostudies-literature
| S-EPMC9273556 | biostudies-literature
| S-EPMC6031334 | biostudies-literature
| S-EPMC5621753 | biostudies-literature
| S-EPMC8037988 | biostudies-literature
| S-EPMC9777386 | biostudies-literature
| S-EPMC8599951 | biostudies-literature